Author: Ken Dropiewski

MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced topline results from the Phase 1b single-ascending dose study of MYK-491.  MYK-491 was generally well-tolerated and increases in cardiac contractility were […]

Shockwave Announces collaboration With Abiomed on Physician Training

SANTA CLARA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — Shockwave Medical, a pioneer in the development and commercialization of intravascular lithotripsy to treat complex calcified cardiovascular disease, today announced an investment and collaboration agreement with Abiomed, Inc. As outlined by the agreement, Abiomed will invest $15 million in Shockwave and […]

Bay Labs Announces Collaboration with Edwards Lifesciences to Utilize AI Software to Improve Heart Disease Detection

SAN FRANCISCO – December 10, 2018 – Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, announced today a collaboration with Edwards Lifesciences focused on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered […]


Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood Clots IRVINE, Calif., Dec. 10, 2018 — Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyze […]

Contego Medical Receives 510(k) Clearance for the Vanguard IEP Peripheral Angioplasty System with Integrated Embolic Protection

RALEIGH, N.C., Dec. 7, 2018 /PRNewswire/ — Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Vanguard IEP® Peripheral Balloon Angioplasty System with Integrated Embolic Protection. Contego Medical is a medical device company developing and commercializing a suite of next-generation devices that address […]

Merit Medical Ireland Wins Medtech Company of the Year Award 2018

SOUTH JORDAN, Utah, Dec. 10, 2018 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that its subsidiary Merit Medical Ireland won the […]

Inari Medical Announces First Patient Enrolled in FLASH Registry Using the FlowTriever System for Pulmonary Embolism

IRVINE, Calif., Dec. 6, 2018 /PRNewswire/ — Inari Medical, Inc. announced today the enrollment of the first patient in the FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (“FLASH”) using the FlowTriever® System for the treatment of pulmonary embolism (PE). FLASH is a 500-patient prospective, multicenter registry study to evaluate real world outcomes […]

Leviticus Cardio Announces Success of Groundbreaking Six Month Chronic Animal Study

PETAH TIKVA, Israel, Dec. 6, 2018 /PRNewswire/ — Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system used with implanted left ventricular assist devices (LVADs), announces the successful completion of a 180-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump. Leviticus’ CET technology compliments […]

HeartFlow Initiates PRECISE Randomized Clinical Trial

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced the start of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial. The first patient was enrolled by Michael C. Turner, M.D., at Imperial Health Cardiovascular Specialists in Lake Charles, LA. The PRECISE trial is designed to compare the usual approach of diagnosing […]

XyloCor Therapeutics Raises $17 Million in Series A Financing to Advance Gene Therapy Portfolio in Cardiovascular Disease

PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, today announced the close of a $17 million Series A financing which was co-led by Sofinnova Ventures and LSP (Life Sciences Partners). Proceeds from the financing will be used […]